Brachytherapy sources
This article was originally published in The Gray Sheet
Executive Summary
FDA guidance issued Aug. 2 recognizes five standards for use in abbreviated 510(k) applications. Cardiovascular brachytherapy devices for prevention of restenosis are not addressed by the document. While the guidance is appropriate for sponsors seeking general claims for photon-emitting brachytherapy sources, specific claims should be handled using the agency's "Guidance for Industry on General/Specific Intended Use"
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.